Projected to be available in 2019, Haselmeier’s subcutaneous drug delivery injection systems for self-administration will be combined with Common Sensing’s Gocap injector monitoring technology to provide a first-of-its-kind, smart disposable injector pen platform.
Haselmeier will sell the platform and expects to attract interest from both existing and new customers. This technology can be used for all injectable drugs that are delivered through an injectable pen.
Detail-oriented means patient-oriented
An estimated 50% of patients do not administer their injectable medications properly which directly can impact treatment outcomes, according to the Swiss-based drug delivery firm Haselmeier.
Smart connected monitoring solutions help users of injectables properly administer their medications to improve efficacy and quality of therapies. With the combined injector pen-Gocap platform, users will have access to the time and amount of every injector dose, along with other details such as storage temperature, according to the company.
Information from the Gocap platform will be made available for a variety of users, including caretakers, clinicians, healthcare systems, researchers and pharmaceutical companies. Gocap dose monitoring was clinically validated for use with insulin pens in studies at Joslin Diabetes Center, in Boston, Massachusetts, and the University of Massachusetts Memorial Medical Center.
“This collaboration allows Haselmeier and Common Sensing to go to market with a connected solution at a much earlier stage in the drug development lifecycle,” James White, president and co-founder of Common Sensing, told us.
“The Haselmeier-Common Sensing platform will be used during clinical trials to monitor compliance, then released for reimbursement as the drug is commercialized,” he added. “Common Sensing's existing Gocap drug monitoring offerings will be unaffected by this collaboration and will continue to grow in parallel.”
White said the pen is inexpensive to produce and is designed to be easy-to-use as well as widely accessible for patients. He adds that while both Common Sensing and Haselmeier “are always open to conversations” about licensing the technology, the primary focus of the partnership at this time is creating and marketing the product.
Common Sensing recently secured $6.6m Series A financing to support injectable medicines. The funds will be used to accelerate Common Sensing's manufacturing and commercial operations specifically for Gocap.
A multi-year history
Haselmeier has devoted the past three years to working with pharmaceutical and biotechnology companies to create mechanical drug delivery solutions. Its most recent D-Flex injector can be used with both fixed-dose or selectable dose regimen.
Haselmeier projects that the recent addition of the Gocap injector monitor to its product portfolio will help pharmaceutical customers quickly launch connected injectable medicines into the market with existing and new pens.
Currently, Haselmeier approximates that nearly 16bn injections of medicine are administered worldwide every year.